Diaccurate Acquires Clinical Stage Sole-in-Class Targeted Cancer Therapy from Merck
“We are very proud that, after a highly competitive selection process, Merck has chosen Diaccurate to bring DIACC3010 into advanced clinical development”, said Dominique Bridon, Ph.D., CEO of Diaccurate.
DIACC3010, formerly M2698, is a Phase II-ready dual PAM inhibitor with rare brain-penetration properties
Merck to become a shareholder of Diaccurate, remains fully committed to the success of the drug candidate
Diaccurate to start exploratory Phase II programs in incurable solid tumors and lymphomas by H2 2022
Acquisition broadens Diaccurate’s sole-in-class oncology and immunotherapy product pipeline and transforms it into a clinical−stage biotech mpany